What is Zymeworks?
Zymeworks operates at the intersection of biotechnology and advanced therapeutic development. The company specializes in the engineering of multifunctional biotherapeutics, with a particular emphasis on oncology and complex disease states. By utilizing its proprietary Azymetric and EFECT platforms, Zymeworks aims to address significant unmet medical needs, positioning itself as a key player in the global biopharmaceutical sector. Its market position is bolstered by a history of strategic partnerships and consistent backing from institutional investors who prioritize long-term value creation in the life sciences domain.
How much funding has Zymeworks raised?
Zymeworks has raised a total of $819.8M across 13 funding rounds:
Multiple Rounds
$22.3M
Multiple Rounds
$34.4M
Series A
$61.5M
Stock Offering
$63.6M
Stock Offering
$97.8M
Stock Offering
$201.3M
Stock Offering
$320.8M
Unspecified (2014): $1M supported by Undisclosed
Share Placement (2014): $17.3M featuring Undisclosed
Corporate Investment (2014): $4M backed by Fonds de Solidarité FTQ
Unspecified (2015): $8.6M with participation from Undisclosed
Unspecified (2015): $24M led by Undisclosed
Unspecified (2015): $1.8M supported by Undisclosed
Series A (2016): $61.5M featuring Northleaf Venture Catalyst Fund, Lumira Capital, Perceptive Advisors, Teralys Capital, BDC Capital, Fonds de Solidarité FTQ, Eli Lilly & Company, Celgene, CTI Life Sciences Fund, Brace Pharma Capital, and Merlin Nexus
Stock Issuance/Offering (2017): $63.6M backed by Undisclosed
Stock Issuance/Offering (2018): $97.8M with participation from Undisclosed
Stock Issuance/Offering (2019): $201.3M led by Undisclosed
Stock Issuance/Offering (2020): $320.8M supported by Undisclosed
Key Investors in Zymeworks
Perceptive Advisors
Founded in 1999 and based in New York, NY, Perceptive Advisors is an investment firm managing around $7 billion in assets, focused on funding innovative healthcare and life sciences technologies.
Teralys Capital
Teralys Capital is dedicated to supporting exceptional technology entrepreneurs in innovating, expanding, and launching tomorrow's ideas on the global market through venture capital and strategic partnerships.
CTI Life Sciences Fund
CTI Life Sciences Fund is a prominent Canadian biotech venture capital firm that focuses on catalyzing innovative ideas and assets into scalable biotech companies, emphasizing long-term value creation.
What's next for Zymeworks?
With the recent influx of $320.8M, Zymeworks is well-positioned to accelerate its clinical development programs and expand its therapeutic reach. The strategic focus will likely remain on the advancement of its lead candidates through rigorous clinical trials, while simultaneously exploring new collaborative opportunities to enhance its intellectual property portfolio. As the company matures, the emphasis will shift toward scaling its operational capabilities and navigating the regulatory pathways necessary for commercialization. This capital deployment is expected to solidify the firm's standing as a leader in the next generation of biotherapeutic innovation, ensuring that its research-driven approach translates into tangible patient outcomes.
See full Zymeworks company page
